Jul 21, 2026 | Press Releases
Brings extensive experience in patient care, dermatologic research and commercializationKing of Prussia, Pennsylvania–(Newsfile Corp. – July 21, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...
Jul 15, 2026 | Press Releases
Securing additional patent protection in the United States, Canada, and Japan for INTASYL CompoundsKing of Prussia, Pennsylvania–(Newsfile Corp. – July 15, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Jun 26, 2026 | Press Releases
Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – June 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...
Jun 25, 2026 | Press Releases
Live virtual fireside chat – investors, advisors, and life sciences analysts invited to attendKing of Prussia, Pennsylvania–(Newsfile Corp. – June 25, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Jun 24, 2026 | Press Releases
Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in next development phaseKing of Prussia, Pennsylvania–(Newsfile Corp. – June 24, 2026) – Phio...
Jun 18, 2026 | Press Releases
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in Phio Pharmaceuticals, to attend the live, interactive presentation and one-on-one meetingsKing of Prussia, Pennsylvania–(Newsfile Corp. – June...